Invalid Symbol

Stock Research for PCYC

Current Price


Latest Update:


Featured Broker: TradeStation

Get the due diligence for another stock.


PCYC Stock Chart & Research Data

The PCYC chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PCYC chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


PCYC Due diligence Resources & Stock Charts

The PCYC stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PCYC Detailed Price Forecast - CNN Money CNN View PCYC Detailed Summary - Google Finance
Yahoo View PCYC Detailed Summary - Yahoo! Finance Zacks View PCYC Stock Research & Analysis -

Stock Analysis

TradeIdeas View PCYC Trends & Analysis - Trade-Ideas Barrons View PCYC Major Holders - Barrons
NASDAQ View PCYC Call Transcripts - NASDAQ Seeking View PCYC Breaking News & Analysis - Seeking Alpha
Spotlight View PCYC Annual Report - OTC Report View PCYC OTC Short Report -
TradeKing View PCYC Fundamentals - TradeKing Charts View PCYC SEC Filings - Bar Chart
WSJ View Historical Prices for PCYC - The WSJ Morningstar View Performance/Total Return for PCYC - Morningstar
MarketWatch View the Analyst Estimates for PCYC - MarketWatch CNBC View the Earnings History for PCYC - CNBC
StockMarketWatch View the PCYC Earnings - StockMarketWatch MacroAxis View PCYC Buy or Sell Recommendations - MacroAxis
Bullish View the PCYC Bullish Patterns - American Bulls Short Pains View PCYC Short Pain Metrics -

Social Media Mentions

StockTwits View PCYC Stock Mentions - StockTwits PennyStocks View PCYC Stock Mentions - PennyStockTweets
Twitter View PCYC Stock Mentions - Twitter Invest Hub View PCYC Investment Forum News - Investor Hub
Yahoo View PCYC Stock Mentions - Yahoo! Message Board Seeking Alpha View PCYC Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for PCYC - Insider Cow View Insider Transactions for PCYC - Insider Cow
CNBC View PCYC Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PCYC - OTC Markets
Yahoo View Insider Transactions for PCYC - Yahoo! Finance NASDAQ View Institutional Holdings for PCYC - NASDAQ

Stock Charts

FinViz View PCYC Stock Insight & Charts - StockCharts View PCYC Investment Charts -
BarChart View PCYC Stock Overview & Charts - BarChart Trading View View PCYC User Generated Charts - Trading View

Latest Financial News for PCYC

Take Advantage Of Donald Trump's Tweets To Buy Top Biotechs
Posted on Friday March 17, 2017

Everytime Donald Trump tweets about drug prices, biotech stocks take it on the chin. Bruce Pile believes these episodes are giving informed investors good entry points for some of the best names in biotech.

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Surprise! Abbvie, not partner J&J, taking over Pharmacyclics for $21B
BioWorld Online - Mar 5, 2015
Investors in Pharmacyclics Inc. are waking up to news that the winning suitor wasn't partner Johnson & Johnson (J&J) as some had speculated but Abbvie Inc., which is paying $261.25 per share in a mix of cash and equity takeover that values the firm at ...
Did AbbVie Just Grossly Overpay for Pharmacyclics Inc.? - Motley Fool

Why AbbVie Inc Spent $21 Billion to Buy Pharmacyclics
Motley Fool - Jan 6, 2016
Chicago-based pharmaceutical company AbbVie (NYSE:ABBV) made a huge move in its purchase of Pharmacyclics for an estimated $21 billion.

The JPMorgan Healthcare Conference kicks off and Pharmacyclics dishes new ...
Motley Fool - Jan 14, 2014
Pharmacyclics was asked no less than a half-dozen questions involving the potential for CLL approval, how the Food and Drug Administration views the opportunity for any expanded indications, and potential CLL labeling restrictions and treatment pricing ...

Why Pharmacyclics Inc. Skyrocketed Higher Today
Motley Fool - Jan 13, 2015
After Gilead Sciences won FDA approval for its cancer drug Zydelig last summer, some investors worried that sales of Johnson & Johnson (NYSE:JNJ) and Pharmacyclics' (NASDAQ:PCYC) Imbruvica, which is approved to treat the same indications as Zydelig ...

Enter a stock symbol to view the stock details.